Introduction
With early initiation of antiretroviral therapy (ART) and greater life expectancy [1] [2] [3] , quality of life (QOL) is an important holistic measure assessing health of persons living with HIV (PLWH). Given the WHO's definition of health as 'a state of complete physical, mental, and social well being, and not merely the absence of disease or infirmity' [4] , QOL reflects one's subjective assessment of physical, emotional, and functional well being [5, 6] . QOL in PLWH on ART has been assessed in a number of studies [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Because HIV-related illnesses and the requirement for life-long medication can both affect QOL, it has become an increasingly important outcome in the comparison of HIV treatment strategies.
We measured QOL in the Strategic Timing of Antiretroviral Therapy (START) study, which enrolled adult PLWH from 35 countries; participants were ARTnaive, had no history of AIDS, were in good health, and had CD4
þ cell counts of above 500 cells/ml [21] ; participants were randomized to either immediate ART initiation or deferring ART until the CD4 þ cell count decreased to less than 350 cells/ml, or until development of AIDS or another condition requiring ART use. Through a mean of 3 years follow-up, the risk of the primary composite endpoint (serious AIDS or non-AIDS events, or death from any cause) was 57% lower in the immediate group.
We previously reported overall high QOL among the primarily healthy population entering this study [19] . In this analysis, we evaluated whether initiation of ART allowed patients to maintain or even improve this QOL, including their self-assessed physical, mental, and overall health status, relative to deferring ART.
Methods
Quality-of-life measures From 2009 to 2013, 4684 participants were enrolled and randomized to the immediate or deferred ART groups. The initial ART regimen was to be consistent with US Department of Health and Human Services guidelines [1] and approved in the country of enrollment, but was not further specified. START was approved by institutional review boards or ethics committees at each clinical site; written consent was obtained from all participants. This analysis includes data accrued through May 2015, when START results were unblinded and ART recommended to all participants in the deferred group.
The QOL measures were obtained at baseline, months 4 and 12, and annually thereafter. Health-related QOL outcomes were assessed by participant self-administered questionnaires, containing a single-item visual analog scale (VAS), and the Short-Form 12-Item Health Survey version 2 (SF-12v2). The VAS asked participants to rate from 0 to 100 their perceived current state of health [22] . The SF-12v2 asked respondents to choose one of three or five responses that best described their self-perceived current or recent physical and mental health [23] . We analyzed three QOL outcome measures derived from the SF-12v2: general health, the physical component summary (PCS) score, and the mental component summary (MCS) score. On the SF-12v2 general health question, participants' perceived general health is selfrated on a 5-item Likert scale; we scored these responses as 0 ('poor'), 20, 50, 80, or 100 ('excellent'). PCS and MCS scores are weighted averages based on responses to all SF-12v2 items, and are standardized to have a mean score of 50 and a standard deviation (SD) of 10 in a US reference population [23] . For all measures, higher values denote better QOL.
Statistical analyses
All analyses were performed for each of the four QOL outcomes, unless noted otherwise. Our primary analysis compared the immediate and deferred groups by intent to treat for changes in QOL from baseline through followup, using longitudinal mixed models adjusted for visit and baseline QOL. Changes from baseline to individual follow-up times were also compared between the treatment groups using unadjusted t tests.
To investigate possible cohort effects, we repeated treatment group comparisons for participants who had 4 or more years of follow-up. Also, to further elucidate the effect of ART, we censored follow-up in the deferred group at ART initiation, and excluded participants from the immediate group who did not start ART within the first year.
To evaluate the effect of clinical events on QOL, we performed three analyses. First, we assessed whether QOL measures declined prior to serious non-AIDS events, serious AIDS events, or all-cause deaths. For those who developed one of these events, we evaluated QOL changes from baseline to the visit immediately prior to the event. Results were compared to QOL changes in eventfree participants, using t tests adjusted for baseline QOL. In order to avoid bias due to shorter follow-up for those with an event, we performed this analysis separately for two follow-up times: QOL visits through month 12, and QOL visits through month 36. For example, we evaluated QOL changes in those developing an event in the first 12 months, compared to changes from baseline to month 12 in those who were event-free during this period. Mean change in QOL was estimated without adjustments.
Second, we assessed whether QOL measures declined after developing serious AIDS or non-AIDS events. For those who developed an event, we evaluated QOL changes from baseline to the first QOL measurement after the event occurred; comparisons to event-free participants followed through 12 and 36 months were as described above. Third, in order to assess whether QOL treatment differences could be explained by different numbers of clinical events developing in immediate and deferred participants, we repeated the primary comparison of change in QOL between these groups after excluding any participant who experienced an event.
We summarized mean changes in CD4 þ cell counts from baseline to each visit with 95% confidence intervals (CIs), and compared treatment groups for changes in CD4 þ cell count throughout follow-up using a longitudinal mixed model adjusted for baseline CD4 þ cell count and visit. In order to assess the effect of changes in CD4 þ cell counts on QOL, we included the time-updated change in CD4 þ cell count in longitudinal mixed models for change in QOL, in addition to baseline QOL, visit, and treatment group indicator.
We previously reported that QOL scores among participants entering this study differed by characteristics such as sex, age, and geographic region [19] . We assessed the homogeneity of the treatment effect on QOL changes across various baseline characteristics in subgroup analyses, by testing for an interaction between subgroup variables with the treatment group indicator in longitudinal mixed models; for subgroups defined by categorizing a continuous variable, the continuous variable was used in the interaction test. The investigated subgroups were prespecified in the START study protocol for the primary endpoint analyses. We also evaluated subgroups based upon the initial prespecified ART regimen including whether or not the regimen included efavirenz, any protease inhibitor, or tenofovir; numbers on other ART drugs were much smaller.
All analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, North Carolina, USA) and R version 3 [24] . All tests were two-sided, and P values of 0.05 or less denoted significance.
Results

Study population
Our analyses included the 4561 (97%) of the START participants who had a baseline and at least one follow-up QOL measure (2262 in the immediate and 2299 in the deferred group). Participants were enrolled from 35 countries. Because translations for the SF-12v2 were not available for participants in Uganda and Nigeria who required questionnaires in their native language, only the VAS was collected for these participants. In total, 4540 participants had a baseline and follow-up VAS, and 4022 answered all 12 items on the SF-12v2 (Fig. 1) .
Baseline characteristics are summarized in Table 1 , and were similar for the immediate and deferred groups. In the immediate group, the prespecified ART regimen contained a non-nucleoside reverse transcriptase inhibitor (NNRTI) for 79% of participants, of which 95% were prespecified efavirenz; for 18% the regimen included a protease inhibitor, and for 4% an integrase inhibitor. The nucleoside/nucleotide (NRTI) regimen included tenofovir for 89%, zidovudine for 8%, and abacavir for 3%.
ART-naïve parƟcipants with CD4+ cell count > 500 cells/μl enrolled in START N=4684 Median follow-up of participants was 3 years (range 4 months to 6 years). ART was used for 95% of follow-up time in the immediate group, and 25% in the deferred group ( 
Immediate ART N=2325
Deferred ART
Quality of life scores by treatment arm
Health-related QOL at study entry was generally high (Table 1) . Mean baseline VAS and perceived general health scores were 80.9 and 72.5, respectively, and mean PCS and MCS scores were 53.7 and 48.2, respectively. Throughout follow-up, changes in all four QOL measures favored the immediate group (P < 0.001) (Fig. 2 ). Estimated differences were as follows: 1.9 (95% CI 1.2-2.5) for the VAS, 3.6 (95% CI 2.8-4.5) for general health perception, 0.8 (95% CI 0.5-1.1) for PCS, and 0.9 (95% CI 0.4-1.3) for MCS. Modest but significant differences were seen as early as 4 months. In the immediate group, VAS (current health) and general health perception improved relative to baseline (especially in the first 24 months), whereas remaining close to baseline in the deferred group. Visual inspection of the four curves suggests that VAS and general health increases above baseline during the first 2 years in the immediate group may have primarily reflected increases in MCS scores, whereas PCS scores remained stable (compared to PCS decreases in the deferred group).
When analyses were limited to participants who had at least 4 years of follow-up, the pattern was similar, with all QOL changes favoring the immediate group ( Participants marked their 'current health' on a visual analog scale (0-100). The general health, PCS, and MCS outcomes were calculated from the SF-12v2 questionnaire.
the deferred group at ART initiation, and excluding 40 participants in the immediate group who did not start ART within the first year, between-group differences were slightly larger, but also followed the same general pattern (Fig. S3 , http://links.lww.com/QAD/B46).
Effect of clinical events on quality of life
For participants who developed a primary clinical event within 12 months, we first evaluated QOL changes from baseline to the visit immediately before the event (Table 2) ; results were compared to QOL changes in those who did not develop a primary event within 12 months. This analysis was repeated for clinical events within 36 months. For example, those with primary events through month 36 had mean declines of À2.6 in VAS and À8.2 in general health scores before developing these events, compared to QOL changes of þ1.5 and þ2.2 among those who did not experience an event through month 36 (each P < 0.001).
Differences were even greater when we evaluated QOL changes from baseline to the visit immediately after a nonfatal event, again compared to those who were eventfree during a given time period (Table 3) . For example, those with an event through month 36 had mean declines of À7.9 in VAS and À14.4 in general health scores after developing these events, compared to increases of þ1.5 and þ2.2 in those without an event (P < 0.001).
Because primary events were associated with a lower QOL, we evaluated whether QOL differences between immediate and deferred groups could be explained by more participants experiencing events in the deferred group. We repeated the analyses shown in Fig. 2 , excluding those who developed a primary event. Differences between the immediate and deferred groups for all four QOL measures were virtually unchanged, with estimated differences of 1.8, 3.6, 0.8, and 0.8 for the VAS, general health, PCS, and MCS scores, respectively (each P < 0.001) (Fig. S4 , http://links.lww.com/QAD/B46). Participants marked their 'current health' on a visual analog scale (0-100). The general health, PCS, and MCS outcomes were calculated from the SF-12v2 questionnaire. Participants marked their 'current health' on a visual analog scale (0-100). The general health, PCS, and MCS outcomes were calculated from the SF-12v2 questionnaire. Effect of CD4 R cell count change on quality of life To determine if immediate-deferred differences could be explained by differences in CD4 þ cell count, we estimated associations of time-updated change in CD4 þ cell counts with change in QOL using longitudinal mixed models. We found that for every 100 cell CD4 þ increase, VAS and general health scores increased by only 0.2 (P < 0.001) and 0.4 points (P < 0.001), respectively. Change in CD4 þ cell count, even if statistically significant, therefore had a quantitatively minimal impact on QOL changes.
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Subgroup analysis
The QOL changes were assessed within and across subgroups formed by different baseline demographic and clinical characteristics; Fig. 3 illustrates the subgroup analyses for the VAS. Across all subgroups, treatment differences favored the immediate group for all QOL outcomes. The estimated immediate-deferred group differences in VAS were similar across all subgroup categories except for sex, when men had a greater difference compared to women (2.3 in men compared to 0.7 in women; P ¼ 0.02 for interaction). VAS differences favoring the immediate group tended to be greater for those with the lower baseline VAS scores, although the differences in treatment effect were not significant (P ¼ 0.15 for interaction between baseline VAS and the subgroup indicator).
The treatment effect on QOL was homogeneous across subgroups formed by different types of ART regimens, including subgroups by whether or not the prespecified regimen contained efavirenz ( Fig. 3 for VAS; P ¼ 0.41 for homogeneity of the treatment effect), protease inhibitors, or tenofovir.
Subgroup analyses for the general health, PCS, and MCS are presented in Fig. S5a -c (http://links.lww.com/QAD/ B46). Since we investigated many subgroups with many comparisons, subgroup analyses should be interpreted with caution due to a possible inflation of type I error. However, changes typically favored the immediate group, and in no case did QOL changes significantly favor the deferred group. In general, differences favoring the immediate group were greatest for those with the lowest baseline QOL scores. For both general health and PCS scores, estimated immediate-deferred group differences in QOL were homogeneous across all subgroup categories except for sex, when men again had a significantly greater difference compared to women; for MCS, group differences were similar across all subgroups including sex.
Discussion
In this population of ART-naive PLWH with CD4 þ cell counts above 500 cells/ml and in good health, we found modest but significant changes in QOL measures favoring the immediate compared to the deferred ART groups for all four QOL measures. This finding was consistent across a variety of subgroups and in multiple sensitivity analyses.
For PLWH using ART, QOL may reflect perceived or real harms from treatment, and also underlying HIV disease. Patients who enrolled in the START study were generally healthy, with relatively high baseline QOL scores [19] , and avoiding decreases in QOL after initiating ART would be a desired outcome. Initiation of ART in those with minimal symptoms has been described as a 'balancing act' between, on the one hand, preventing HIV disease and improving survival, and, on the other hand, not exposing patients to ART side effects [7, 25] . Such adverse events include gastrointestinal symptoms, neuropsychiatric problems, or metabolic abnormalities, although newer ART drugs are associated with fewer side effects than older regimens [1, 16] . For patients who started ART immediately, the goal of avoiding decreases in QOL after drug initiation was met. During the first 24 months after beginning ART, QOL for all four measures increased or remained stable, and was consistently above QOL in the deferred group.
Why participants in the immediate arm benefited to a greater degree in QOL measures is not entirely clear.
Increases in CD4
þ cell count were associated only with very small changes in QOL scores within treatment groups. Given that almost all participants suppressed HIV viral load while using ART, one cannot separate change in viral load from other ART effects. Although QOL was poorer in those who developed a primary clinical event, our analysis also indicated that lower QOL in the deferred group could not be explained solely by their developing a higher number of such events; when excluding those with primary events, our results for treatment group differences were virtually unchanged.
One possible explanation for our results is that deferred participants had a greater number of clinical symptoms and minor illnesses not meeting the criteria for clinical events, but reflected in poorer self-assessed physical QOL; the decline in PCS scores in this group over the first 3 years would be consistent with this hypothesis. A second possibility is that initiating ART may have led to improvements in self-perceived emotional status in the immediate group. The early increase in MCS scores in this group would be consistent with this hypothesis. Participants were not blinded to treatment arm, and some patients may have been encouraged by the belief that initiating ART represented a positive intervention in the management of their HIV infection. Other participants who feared serious ART side effects may have felt relief if they did not occur. Further studies evaluating these theories are important areas for investigation. Estimates within each subgroup were calculated using longitudinal mixed models that contained visit, baseline QOL, and treatment group indicator. An interaction P value 0.05 or less is evidence for heterogeneity in the treatment effect across the subgroups; the estimates and P values for the interaction between the treatment group indicator and the participant characteristic defining the subgroups were calculated using longitudinal mixed models that contained baseline QOL, visit, and subgroup and treatment group indicators. For subgroups that were formed by discretizing continuous variables (e.g. age), the interaction effect was estimated using the continuous variable. Additionally, subgroups by ART type were analyzed for participants whose prespecified ART regimen contained (or did not contain) protease inhibitors (17.6% of participants), or tenofovir (88.4%). Treatment effects were homogeneous across these subgroups. ART, antiretroviral therapy; QOL, quality of life.
Although the treatment effect on QOL was statistically significant, group differences and changes from baseline were relatively modest. On a scale of 0-100, estimated differences between the immediate and deferred ART groups were 1.9 for VAS and 3.6 for perceived general health. Several factors may have limited the potential for larger QOL differences. Because study enrollees were healthy with higher CD4 þ cell counts, we would not expect dramatic decreases in QOL after entering the study, even in the absence of ART. Confirming this expectation, in deferred group participants not on ART, VAS and general health scores did not decrease for the first 24 months. In addition, because many participants entered the study with already high scores, there was limited room for further large increases. Supporting this argument, QOL score differences favoring the immediate ART initiation group were greatest for persons with the lowest baseline QOL scores. Nevertheless, despite all these factors, immediate ART resulted in higher QOL than deferred ART over the first few years.
Our conclusions of a positive impact of ARTon QOL are consistent with other studies. In a study comparing continuous ART to CD4
þ -guided episodic ART use, group differences through 36 months favoring continuous use were þ1.20 for VAS and þ2.07 for general health [8] . In another study of patients starting ART primarily with advanced HIV disease (median CD4 þ cell counts of 162.5 cells/ml and 38% with AIDS illnesses), PCS and MCS scores (45.3 and 42.9 at baseline) improved through 12 months by þ2.6 and þ1.8, respectively [26] .
In our analysis of demographic and clinical subgroups, QOL changes consistently favored the immediate group over a wide variety of participant characteristics. Our finding of greater immediate-deferred differences among men compared to women should be interpreted with caution, because we evaluated many subgroups, and because our study was not designed to specifically evaluate sex differences in self-assessed QOL, which may be influenced by many factors [25, 27] . Our finding that treatment arm differences were significantly greater for men than women in PCS, but not MCS scores, suggests sex differences on overall QOL life measures (VAS and general health) primarily reflect greater improvement among men in self-assessed physical symptoms; reasons for such differences require additional evaluation.
More than three-quarters of ART regimens used contained an NNRTI, almost always efavirenz, and two NRTIs that most often included tenofovir. Our subgroup analysis found that QOL changes favored the immediate group irrespective of the prespecified ART regimen, and the size of the treatment effect was homogeneous across the subgroups by prespecified efavirenz, protease inhibitors, or tenofovir. These results need to be interpreted with caution, however, since the START study was not designed to determine whether specific ART drugs or regimens differentially affect QOL. Prespecified regimens were investigator-determined, and decisions concerning which drug to use may have been based on various clinical considerations. Nevertheless, our analysis does suggest that those on different regimens all benefitted from earlier ART initiation.
Our QOL measures were based upon the SF-12v2 questionnaire and the VAS. Although containing only 12 items, the SF-12 was derived from the larger SF-36, and has been demonstrated to be a reliable and valid measure of this larger scale [28] [29] [30] . The VAS has also been shown to be a valid and reliable measure when evaluated against longer multiitem scales for overall QOL [22] . Although longer-item QOL surveys may give more precise data on specific subdomains, the VAS and SF-12v2 provide valid summary information, and are practical and efficient in settings such as large trials where multiple other data collection forms are also required.
Apart from absence of blinding to treatment arm, our study has several other limitations. Those from different regions and cultures may attach different interpretations and significance to specific symptoms or functional status, affecting how they respond to specific QOL items [19, 31, 32] . PCS and MCS scores were standardized based upon US populations [23] , and the significance of a specific numerical QOL score may vary across countries. However, because of randomization, and because we investigated within-patient changes from baseline, such differences should minimally affect our treatment comparisons and our overall conclusion that immediate ART initiation contributes to a more favorable subjective sense of well being. In addition, our results are consistent with the superiority of early ARTas reported for major clinical outcomes in the START study, where events were adjudicated by a blinded endpoint review committee [21] .
In summary, in this large randomized clinical trial of ARTnaive PLWH from multiple countries who were in generally good health and who had above 500 CD4 þ cells/ ml at enrollment, there were modest but significant QOL improvements during follow-up in those immediately initiating ART compared to those who deferred treatment. Our conclusions held for measures of overall general health, for summary scales of physical and mental health and well being, for different sensitivity analyses, and were consistent across various participant characteristics. The improvement in patient-perceived health with immediate ART adds to the growing body of evidence that supports recommendations to start ART as soon as possible after HIV diagnosis, irrespective of CD4 þ cell count [1, 2] .
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